Accession Number:

ADA621496

Title:

Acinetobacter Species Infections among Navy and Marine Corps Beneficiaries: 2014 Annual Report

Descriptive Note:

Annual rept. 1 Jan-31 Dec 2014

Corporate Author:

NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA EPIDATA CENTER DEPT

Personal Author(s):

Report Date:

2015-07-20

Pagination or Media Count:

35.0

Abstract:

Since the early 2000s, health professionals are increasingly concerned about Acinetobacter species infections due to demonstrated ability to develop resistance to multiple antibiotics, limiting treatment options. In 2014, Acinetobacter incidence was 3.2 and 4.7 per 100,000 persons per year in the Department of the Navy DON and the Department of Defense DOD, respectively, both of which were a slight increase from 2013. Active duty Marines had a higher burden than that of any other service members. Acinetobacter species, not otherwise specified, was the most common etiologic agent in 2014. In the DON, a decrease in the overall burden of resistance was observed, as well as an overall decrease in the severity of resistance seen. For non-multidrug-resistant MDR cases in the DON and DOD, providers often prescribed trimethoprimsulfamethoxazole, consistent with 2012 observations. For multidrug-resistant cases in 2014, DON providers most commonly prescribed cefazolin DOD providers most commonly prescribed ciprofloxacin and trimethoprimsulfamethoxazole for these cases. Although slightly different from 2013, 2014 prescribing patterns were consistent with recommendations. Among DON beneficiaries organisms were most susceptible to gentamicin while least susceptible to ceftriaxone. Among DOD beneficiaries, organisms were most susceptible to ampicillinsulbactam and least susceptible to nitrofurantoin, similar to past observations for the DON and DOD. An overall increase in susceptibility for most antibiotics was identified.

Subject Categories:

  • Biology
  • Medicine and Medical Research
  • Microbiology
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE